BSEM logo

BIOSTEM TECHNOLOGIES INC

BSEMNASDAQ
🏆 #4300 by market capUS Equity
$3.88▼ $0.19 (−5.02%)
After hours · at close
🔔
Track BSEM
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.0%
7d▼ 4.9%
14d▼ 3.4%
30d▲ 5.6%
ytd—
1y—
🏦Market Cap
$66M
Small Cap
📈Revenue Growth (YoY)
-84.3%
Declining
📊Gross Margin
113.9%
High
💵FCF Margin
14.6%
Healthy
⚖️P/S Ratio
-1.1x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$3.85 – $3.94
52-Week Range
$2.25 – $8.40
Volume
$2.11B
Avg Volume
$2.54B
Shares Outstanding
17.0M
Next Earnings
Nov 3, 2026

Fundamentals Snapshot

Annual Revenue
$47M
Last Q Revenue
$8M
P/E Ratio
-2.4
P/S Ratio
-1.1x
EPS (TTM)
$-1.63
Dividend Yield
0.00%
Dilution (1yr)
−26.7%

Why Investors Own BSEM

  • ✓High-growth profile — revenue up +28.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 65% gross margin and 27% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BSEM logo

BIOSTEM TECHNOLOGIES INC

BSEM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$47M▼ −84.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
93.1%▼ −2.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$689K▼ −102.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$7M▼ −72.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
16.7M▼ −26.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$26M▲ +$8M YoY
StockOtter · stockotter.space

About BIOSTEM TECHNOLOGIES INC

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Reuters·2h ago

BIOSTEM TECHNOLOGIES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift BSEM price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

BIOSTEM TECHNOLOGIES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.